From Promise to Reality: Advancing Cell Therapies Beyond Oncology

The 4th Cell Therapy for Autoimmune Disease Summit returns to Philadelphia as the only industry-focused meeting uniting developers working across autologous, allogeneic, and in vivo cell therapy approaches for autoimmune disease. Bringing together pioneering biotech, pharma, and academic leaders, the summit will explore the latest advances across lupus, multiple sclerosis, rheumatoid arthritis, and rare autoimmune indications.

The timing has never been more important. Following breakthrough proof-of-concept studies and early clinical successes, 2026 is set to deliver a wave of highly anticipated clinical updates across multiple cell therapy modalities. As developers race toward commercially viable, disease-modifying therapies, the field must now address the challenges of safety, scalability, durability, and patient access.

With dedicated tracks covering Preclinical Development & Translation and Clinical Development, gain practical insights from leaders at Artiva Biotherapeutics, Cabaletta Bio, PolTREG, Orca Bio, Overland Therapeutics, and more as they share the latest innovations shaping the future of immune reset therapies.